Which has preferable earnings and valuation, PGNY or FLGT?

Progyny has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.52 $58.52M $0.77 32.45 Fulgent Genetics $322.67M 1.60 -$60.51M -$2.39 N/A

Does the media refer more to PGNY or FLGT?

In the previous week, Progyny had 6 more articles in the media than Fulgent Genetics. MarketBeat recorded 13 mentions for Progyny and 7 mentions for Fulgent Genetics. Progyny's average media sentiment score of 0.74 beat Fulgent Genetics' score of 0.35 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor FLGT or VRDN?

In the previous week, Fulgent Genetics had 4 more articles in the media than Viridian Therapeutics. MarketBeat recorded 7 mentions for Fulgent Genetics and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.88 beat Fulgent Genetics' score of 0.35 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viridian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FLGT or SGRY?

In the previous week, Fulgent Genetics had 5 more articles in the media than Surgery Partners. MarketBeat recorded 7 mentions for Fulgent Genetics and 2 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.50 beat Fulgent Genetics' score of 0.35 indicating that Surgery Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Surgery Partners 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SNDA or FLGT?

In the previous week, Fulgent Genetics had 2 more articles in the media than Sonida Senior Living. MarketBeat recorded 7 mentions for Fulgent Genetics and 5 mentions for Sonida Senior Living. Fulgent Genetics' average media sentiment score of 0.35 beat Sonida Senior Living's score of 0.17 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonida Senior Living 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Fulgent Genetics (FLGT) Competitors

$18.14 -0.56 (-2.99%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$18.13 -0.01 (-0.06%)

As of 06/3/2026 04:10 PM Eastern

Compare

FLGT vs. PGNY, VRDN, SGRY, ADUS, and SNDA

Should you buy Fulgent Genetics stock or one of its competitors? MarketBeat compares Fulgent Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fulgent Genetics include Progyny (PGNY), Viridian Therapeutics (VRDN), Surgery Partners (SGRY), Addus HomeCare (ADUS), and Sonida Senior Living (SNDA). These companies are all part of the "healthcare" industry.

How does Fulgent Genetics compare to Progyny?

Progyny (NASDAQ:PGNY) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Progyny had 6 more articles in the media than Fulgent Genetics. MarketBeat recorded 13 mentions for Progyny and 7 mentions for Fulgent Genetics. Progyny's average media sentiment score of 0.74 beat Fulgent Genetics' score of 0.35 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Progyny has a net margin of 5.23% compared to Fulgent Genetics' net margin of -23.04%. Progyny's return on equity of 13.34% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

94.9% of Progyny shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 9.9% of Progyny shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Progyny has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.52	$58.52M	$0.77	32.45
Fulgent Genetics	$322.67M	1.60	-$60.51M	-$2.39	N/A

Progyny has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Progyny presently has a consensus target price of $29.67, suggesting a potential upside of 18.71%. Fulgent Genetics has a consensus target price of $27.00, suggesting a potential upside of 48.84%. Given Fulgent Genetics' higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Progyny beats Fulgent Genetics on 14 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Viridian Therapeutics?

Fulgent Genetics (NASDAQ:FLGT) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Fulgent Genetics presently has a consensus price target of $27.00, indicating a potential upside of 48.84%. Viridian Therapeutics has a consensus price target of $36.14, indicating a potential upside of 121.06%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Fulgent Genetics has higher revenue and earnings than Viridian Therapeutics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.60	-$60.51M	-$2.39	N/A
Viridian Therapeutics	$70.85M	23.79	-$342.60M	-$3.32	N/A

In the previous week, Fulgent Genetics had 4 more articles in the media than Viridian Therapeutics. MarketBeat recorded 7 mentions for Fulgent Genetics and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.88 beat Fulgent Genetics' score of 0.35 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viridian Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.1% of Fulgent Genetics shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fulgent Genetics has a net margin of -23.04% compared to Viridian Therapeutics' net margin of -490.31%. Fulgent Genetics' return on equity of -3.24% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-23.04%	-3.24%	-2.97%
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

Fulgent Genetics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Summary

Fulgent Genetics beats Viridian Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Surgery Partners?

Fulgent Genetics (NASDAQ:FLGT) and Surgery Partners (NASDAQ:SGRY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

48.1% of Fulgent Genetics shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by insiders. Comparatively, 2.0% of Surgery Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Fulgent Genetics had 5 more articles in the media than Surgery Partners. MarketBeat recorded 7 mentions for Fulgent Genetics and 2 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.50 beat Fulgent Genetics' score of 0.35 indicating that Surgery Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Surgery Partners has a net margin of -2.28% compared to Fulgent Genetics' net margin of -23.04%. Surgery Partners' return on equity of 1.04% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-23.04%	-3.24%	-2.97%
Surgery Partners	-2.28%	1.04%	0.41%

Fulgent Genetics has higher earnings, but lower revenue than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.60	-$60.51M	-$2.39	N/A
Surgery Partners	$3.31B	0.53	-$77.90M	-$0.60	N/A

Fulgent Genetics currently has a consensus price target of $27.00, indicating a potential upside of 48.84%. Surgery Partners has a consensus price target of $22.18, indicating a potential upside of 64.19%. Given Surgery Partners' stronger consensus rating and higher probable upside, analysts plainly believe Surgery Partners is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Fulgent Genetics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Surgery Partners has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

Summary

Surgery Partners beats Fulgent Genetics on 10 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Addus HomeCare?

Fulgent Genetics (NASDAQ:FLGT) and Addus HomeCare (NASDAQ:ADUS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Addus HomeCare has a net margin of 6.89% compared to Fulgent Genetics' net margin of -23.04%. Addus HomeCare's return on equity of 9.80% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-23.04%	-3.24%	-2.97%
Addus HomeCare	6.89%	9.80%	7.34%

Addus HomeCare has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.60	-$60.51M	-$2.39	N/A
Addus HomeCare	$1.42B	1.16	$95.91M	$5.41	16.36

Fulgent Genetics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Addus HomeCare has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Fulgent Genetics presently has a consensus price target of $27.00, indicating a potential upside of 48.84%. Addus HomeCare has a consensus price target of $131.22, indicating a potential upside of 48.29%. Given Fulgent Genetics' higher probable upside, research analysts plainly believe Fulgent Genetics is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 95.4% of Addus HomeCare shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 4.1% of Addus HomeCare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Fulgent Genetics had 6 more articles in the media than Addus HomeCare. MarketBeat recorded 7 mentions for Fulgent Genetics and 1 mentions for Addus HomeCare. Addus HomeCare's average media sentiment score of 1.89 beat Fulgent Genetics' score of 0.35 indicating that Addus HomeCare is being referred to more favorably in the news media.

Company	Overall Sentiment
Fulgent Genetics	Neutral
Addus HomeCare	Very Positive

Summary

Addus HomeCare beats Fulgent Genetics on 12 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Sonida Senior Living?

Sonida Senior Living (NYSE:SNDA) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Fulgent Genetics has a net margin of -23.04% compared to Sonida Senior Living's net margin of -24.15%. Fulgent Genetics' return on equity of -3.24% beat Sonida Senior Living's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonida Senior Living	-24.15%	-36.98%	-7.08%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

Sonida Senior Living presently has a consensus target price of $40.50, suggesting a potential upside of 20.45%. Fulgent Genetics has a consensus target price of $27.00, suggesting a potential upside of 48.84%. Given Fulgent Genetics' higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Sonida Senior Living.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonida Senior Living	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

87.6% of Sonida Senior Living shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 39.3% of Sonida Senior Living shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Fulgent Genetics has lower revenue, but higher earnings than Sonida Senior Living. Fulgent Genetics is trading at a lower price-to-earnings ratio than Sonida Senior Living, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonida Senior Living	$381.14M	4.18	-$70.78M	-$5.83	N/A
Fulgent Genetics	$322.67M	1.60	-$60.51M	-$2.39	N/A

In the previous week, Fulgent Genetics had 2 more articles in the media than Sonida Senior Living. MarketBeat recorded 7 mentions for Fulgent Genetics and 5 mentions for Sonida Senior Living. Fulgent Genetics' average media sentiment score of 0.35 beat Sonida Senior Living's score of 0.17 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sonida Senior Living	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fulgent Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sonida Senior Living has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Summary

Fulgent Genetics beats Sonida Senior Living on 9 of the 14 factors compared between the two stocks.

Get Fulgent Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGT vs. The Competition

Export

Metric	Fulgent Genetics	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$531.09M	$1.57B	$6.47B	$12.54B
Dividend Yield	N/A	N/A	2.69%	5.22%
P/E Ratio	-7.59	77.62	22.39	24.18
Price / Sales	1.60	6.92	520.79	112.26
Price / Cash	N/A	22.87	41.34	57.13
Price / Book	0.51	4.77	9.84	6.72
Net Income	-$60.51M	-$54.76M	$3.57B	$337.19M
7 Day Performance	1.34%	-0.78%	-1.16%	0.48%
1 Month Performance	28.38%	4.20%	3.85%	5.07%
1 Year Performance	-14.31%	-3.40%	27.40%	34.25%

Fulgent Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGT Fulgent Genetics	3.0873 of 5 stars	$18.14 -3.0%	$27.00 +48.8%	-14.3%	$531.09M	$322.67M	N/A	1,315
PGNY Progyny	4.5751 of 5 stars	$25.12 -4.1%	$29.67 +18.1%	+13.7%	$2.00B	$1.29B	33.08	310	Analyst Forecast Insider Trade Buyback Announcement
VRDN Viridian Therapeutics	3.9591 of 5 stars	$15.87 -6.4%	$36.14 +127.8%	+13.1%	$1.75B	$70.92M	N/A	50
SGRY Surgery Partners	4.2783 of 5 stars	$13.72 +3.8%	$22.18 +61.7%	-42.0%	$1.75B	$3.34B	N/A	16,000	Positive News
ADUS Addus HomeCare	4.3267 of 5 stars	$90.42 +1.1%	$131.22 +45.1%	-21.5%	$1.71B	$1.45B	16.69	50,659	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGT) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulgent Genetics (FLGT) Competitors

FLGT vs. PGNY, VRDN, SGRY, ADUS, and SNDA

How does Fulgent Genetics compare to Progyny?

Summary

How does Fulgent Genetics compare to Viridian Therapeutics?

Summary

How does Fulgent Genetics compare to Surgery Partners?

Summary

How does Fulgent Genetics compare to Addus HomeCare?

Summary

How does Fulgent Genetics compare to Sonida Senior Living?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulgent Genetics (FLGT) Competitors

FLGT vs. PGNY, VRDN, SGRY, ADUS, and SNDA

How does Fulgent Genetics compare to Progyny?

Does the media refer more to PGNY or FLGT?

Is PGNY or FLGT more profitable?

Do insiders & institutionals have more ownership in PGNY or FLGT?

Which has preferable earnings and valuation, PGNY or FLGT?

Which has more risk and volatility, PGNY or FLGT?

Do analysts rate PGNY or FLGT?

Summary

How does Fulgent Genetics compare to Viridian Therapeutics?

Do analysts rate FLGT or VRDN?

Which has preferable valuation and earnings, FLGT or VRDN?

Does the media favor FLGT or VRDN?

Do insiders and institutionals believe in FLGT or VRDN?

Is FLGT or VRDN more profitable?

Which has more risk & volatility, FLGT or VRDN?

Summary

How does Fulgent Genetics compare to Surgery Partners?

Do insiders and institutionals believe in FLGT or SGRY?

Does the media favor FLGT or SGRY?

Is FLGT or SGRY more profitable?

Which has stronger valuation and earnings, FLGT or SGRY?

Do analysts prefer FLGT or SGRY?

Which has more volatility & risk, FLGT or SGRY?

Summary

How does Fulgent Genetics compare to Addus HomeCare?

Is FLGT or ADUS more profitable?

Which has higher valuation & earnings, FLGT or ADUS?

Which has more risk & volatility, FLGT or ADUS?

Do analysts prefer FLGT or ADUS?

Do institutionals and insiders believe in FLGT or ADUS?

Does the media favor FLGT or ADUS?

Summary

How does Fulgent Genetics compare to Sonida Senior Living?

Is SNDA or FLGT more profitable?

Do analysts recommend SNDA or FLGT?

Do insiders & institutionals hold more shares of SNDA or FLGT?

Which has higher earnings & valuation, SNDA or FLGT?

Does the media prefer SNDA or FLGT?

Which has more volatility & risk, SNDA or FLGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools